Relmada Therapeutics (RLMD) Depreciation and Depletion (2013 - 2021)

Relmada Therapeutics (RLMD) has 9 years of Depreciation and Depletion data on file, last reported at $452.0 in Q2 2021.

• On a quarterly basis, Depreciation and Depletion fell 56.07% year-over-year to $452.0 in Q2 2021; TTM through Dec 2021 was $1258.0, a 66.47% decrease from a year earlier, with the FY2021 full-year figure at $1258.0, down 66.47% from the prior year.
• Depreciation and Depletion for Q2 2021 stood at $452.0, down from $806.0 in the prior quarter.
• Over the last five years, Depreciation and Depletion for RLMD reached as high as $23268.0 in Q1 2017 and fell as low as -$556.0 in Q4 2018.
• Historically, Depreciation and Depletion has averaged $3399.1 across 5 years, with a median of $1029.0 in 2020.
• Across the five-year window, Depreciation and Depletion plunged 195.53% in 2018 and jumped 495.68% in 2019, its largest moves.
• Year by year, Depreciation and Depletion stood at $582.0 in 2017, then slumped by 195.53% to -$556.0 in 2018, then soared by 495.68% to $2200.0 in 2019, then sank by 62.59% to $823.0 in 2020, then plunged by 45.08% to $452.0 in 2021.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $452.0 in Q2 2021, $806.0 in Q1 2021, and $823.0 in Q4 2020.